IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal

IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal

Hypoglycemia is a rare paraneoplastic manifestation of patients with neoplasms. Hypoglycemia can be induced by several causes, including an aberrant increase of hypoglycemic agents and adrenal insufficiency. Sorafenib is the first agent to demonstrate a survival benefit in the treatment of advanced...

Full description

Bibliographic Details
Main Authors: Kazuya Okushin, Yoshinari Asaoka, Izumi Fukuda, Naoto Fujiwara, Tatsuya Minami, Masaya Sato, Shintaro Mikami, Koji Uchino, Kenichiro Enooku, Yuji Kondo, Ryosuke Tateishi, Tadashi Goto, Shuichiro Shiina, Haruhiko Yoshida, Kazuhiko Koike
Format: Article
Language:English
Published: Karger Publishers 2012-12-01
Series:Case Reports in Gastroenterology
Subjects:
IGF-II
Hepatocellular carcinoma
Sorafenib
Metabolic complications
Molecular targeting therapy
IGF signal
Hypoglycemia
Online Access:http://www.karger.com/Article/FullText/346462

Internet

http://www.karger.com/Article/FullText/346462

Similar Items